Funding The SAVE study was supported in part by the University of Manitoba; Shared Health Manitoba, the National Microbiology Laboratory-Public Health Agency of Canada (PHAC-NML); Merck Canada Inc. and Pfizer Canada Inc. Transparency declarations None to declare. Invasive pneumococcal disease (IPD) is an ongoing threat to global health, with severe socio-economic impacts, and MDR I S. pneumoniae i is a potentially emerging concern amongst IPD. SAVE is an ongoing, annual, national study between the Canadian Antimicrobial Resistance Alliance (CARA) and the National Microbiology Laboratory, focused on characterizing invasive isolates of I S. pneumoniae i obtained across Canada. [Extracted from the article]